US Stock Insider Trading | Axsome Therapeutics disclosed one insider transaction on February 23

K-LinePoet · 2026-02-26T08:40:42+00:00

Axsome Therapeutics recently disclosed insider trading activity, with director Coleman Mark purchasing 12,500 shares on February 20, 2026, at a price of $4.95, totaling approximately $61,800. The company focuses on the development of biopharmaceuticals for central nervous system disorders, dedicated to providing new treatment options.

K-LinePoet

2026-02-26 08:40:42

Abstract generation in progress

On February 23, 2026, Axsome Therapeutics (AXSM) disclosed an insider trading activity. Director Coleman Mark purchased 12,500 shares on February 20, 2026.

[Recent Insider Trades]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 23, 2026	Director	Coleman Mark	February 20, 2026	Buy	12,500	4.95	62,500
February 10, 2026	Director	Coleman Mark	February 10, 2026	Buy	5,193	8.02	41,600
February 2, 2026	Shareholder with >10%	TABUTEAU HERRIOT	February 2, 2026	Sell	32,400	185.60	6,015,300
February 2, 2026	Shareholder with >10%	TABUTEAU HERRIOT	February 2, 2026	Buy	32,400	8.02	259,900
January 23, 2026	Executive	Maizel Ari	January 21, 2026	Buy	7,500	70.73	530,500
January 23, 2026	Executive	Pizzie Nick	January 22, 2026	Buy	12,000	3.50	42,000
January 23, 2026	Executive	Pizzie Nick	January 22, 2026	Sell	12,000	187.92	2,255,000
January 23, 2026	Executive	Maizel Ari	January 21, 2026	Sell	7,500	184.44	1,383,300
January 2, 2026	Director	Saad Mark E	December 31, 2025	Sell	37,600	165.18	6,207,000
January 2, 2026	Director	Saad Mark E	December 31, 2025	Buy	6,231	8.02	50,000

[Company Information]

Axsome Therapeutics, Inc. was founded in January 2012. The company is a clinical-stage biopharmaceutical firm developing new treatments for pain and other central nervous system or neurological disorders. By focusing on this therapeutic area, they aim to address a significant and growing market where current treatment options are limited or inadequate. Their goal is to become a fully integrated biopharmaceutical company that develops and commercializes therapies to improve the lives of patients suffering from pain and other central nervous system diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.